Future innovations in treating advanced prostate cancer (Q36456511)

14 August 2017

1 reference

title

Future innovations in treating advanced prostate cancer (English)

1 reference

14 August 2017

Pratik Desai

1

1 reference

14 August 2017

Juan A Jiménez

series ordinal

2

1 reference

14 August 2017

Chinghai Kao

series ordinal

3

1 reference

14 August 2017

Thomas A Gardner

series ordinal

4

1 reference

14 August 2017

publication date

1 May 2006

1 reference

Urologic Clinics of North America

14 August 2017

published in

1 reference

14 August 2017

volume

33

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

247-72, viii

1 reference

14 August 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Tumor response to radiotherapy regulated by endothelial cell apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Tumor angiogenesis: therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Induction of angiogenesis during the transition from hyperplasia to neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Both v-Ha-Ras and v-Raf Stimulate Expression of the Vascular Endothelial Growth Factor in NIH 3T3 Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Formation of endothelial cell networks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Vascular endothelial growth factor is a secreted angiogenic mitogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Extracellular matrix and cell shape: potential control points for inhibition of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Involvement of Urokinase and its Receptor in the Invasiveness of Human Prostatic Carcinoma Cell Lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Expression of cyclooxygenase-2 in prostate carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenin monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Thrombospondins as anti-angiogenic therapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Thalidomide is an inhibitor of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Angiostatin induces and sustains dormancy of human primary tumors in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Redefining the target: chemotherapeutics as antiangiogenics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Local intratumoral tumor necrosis factor-alpha and systemic IFN-alpha 2b in patients with locally advanced prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Phase II trial of GM-CSF in advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Dendritic cells injected via different routes induce immunity in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Adenovirus p16 gene therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Antisense c-myc retroviral vector suppresses established human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Osteocalcin is incompletely spliced in non-osseous tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Vitamin D-responsive protein-DNA interactions at multiple promoter regulatory elements that contribute to the level of rat osteocalcin gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Regulated expression of the bone-specific osteocalcin gene by vitamins and hormones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Transforming growth factor-beta 1 responsiveness of the rat osteocalcin gene is mediated by an activator protein-1 binding site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

An AML-1 consensus sequence binds an osteoblast-specific complex and transcriptionally activates the osteocalcin gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Osteocalcin-directed gene therapy for prostate-cancer bone metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Prostate-specific antigen expression is regulated by an upstream enhancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Delivery of adenoviral vectors to the prostate for gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

NFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane-antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Replicative senescence and cell immortality: the role of telomeres and telomerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Specific Association of Human Telomerase Activity with Immortal Cells and Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

p53, the cellular gatekeeper for growth and division

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Ad5CMVp53 gene therapy for locally advanced prostate cancer--where do we stand?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Role of the p16 tumor suppressor gene in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Cdc25 cell-cycle phosphatase as a target of c-myc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Viral vectors for gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

The role of vitamin D in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Identification and characterization of a new member of the TNF family that induces apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

The receptor for the cytotoxic ligand TRAIL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Fas ligand gene transfer prolongs rat renal allograft survival and down-regulates anti-apoptotic Bag-1 in parallel with enhanced Th2-type cytokine expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

From TGF-beta to cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Molecular regulation and biological function of adenovirus early genes: the E4 ORFs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

An adenoviral vector containing an arg-gly-asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.12.005

10.1016/J.UCL.2005.12.005

7 January 2021

Identifiers

DOI

1 reference

14 August 2017

1 reference